HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated

Interferon Alfa-2b

Hui Ma;Rui-Feng Yang;Xiao-He Li;Qian Jin;Lai Wei

【期刊名称】《中华医学杂志（英文版）》 【年(卷),期】2016(129)018

【摘要】Background:We aimed to evaluate the usefulness of serum hepatitis B virus core-related antigens (HBcrAg) for predicting hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients treated with conventional interferon (IFN) alfa-2b or pegylated IFN.Methods:Fifty-eight patients were enrolled:29 for the training group and 29 for the validating group.HBcrAg was measured at baseline,week 12,end of the treatment,and 12-and 24-week follow-ups.Sixteen patients in the training group were enrolled in the long-term follow-up (LTFU),during which time the dynamics of the HBcrAg was monitored.Results:The serum HBcrAg level gradually declined during treatment among the HBeAg seroconversion patients of the training group (from baseline,week 12,end of the treatment,12-week follow-up to 24-week follow-up were 110,245 kU/ml,3760 kU/ ml,7410 kU/ml,715 kU/ml,200 kU/ml,respectively).HBcrAg ＜19,565 kU/ml at week 24,HBcrAg ＜34,225 kU/ml at 12-week follow-up,and HBcrAg decrease ≥0.565 log10 kU/ml from the baseline to the end of treatment